Mouse Hybridoma for Monoclonal Antibody Discovery

Originally established as a specialist hybridoma company in 2001, Fusion Antibodies has more than two decades of experience delivering customised antibody discovery solutions for biotechnology and pharmaceutical organisations. Today, we combine proven hybridoma expertise with modern screening technologies, sequencing, engineering and developability assessment to support efficient progression towards therapeutic candidates.

Why Choose Mouse Hybridoma for Antibody Discovery?

Mouse hybridoma technology generates stable antibody-producing cell lines by fusing antigen-specific B cells with immortal myeloma cells. This enables the production of highly specific monoclonal antibodies with defined binding characteristics and provides a robust foundation for downstream antibody engineering.

Mouse hybridoma remains particularly valuable for:

• Therapeutic antibody discovery
• Functional antibody generation
• Research-grade monoclonal antibodies
• Diagnostic assay development
• Antibodies against complex protein targets
• Recombinant antibody development following sequence recovery

Our scientific team works collaboratively with each client to understand the target biology, intended application and final antibody format before designing an appropriate discovery strategy.

Our Mouse Hybridoma Discovery Workflow

Target Assessment and Antigen Design

Successful antibody discovery begins with careful target evaluation. We design immunogens that maximise the likelihood of generating antibodies against biologically relevant epitopes while reducing downstream development challenges.

Our antigen design capabilities include:

• Recombinant antigen expression and purification
• Native protein and conformational epitope design
• Carrier protein conjugation where appropriate
• Optimised adjuvant selection
• Quality assessment for purity, integrity and functionality

A well-designed antigen is often the single most important factor influencing hybridoma success

Immunisation Strategy

Each immunisation programme is tailored to the target and project objectives. Multiple animals are typically included to maximise immune diversity and increase the probability of identifying high-quality antibody candidates.

Our approach includes:

• Optimised dosing schedules
• Appropriate administration routes
• Serum titre monitoring
• Immune response evaluation prior to fusion

Hybridoma Generation and Fusion

Fusion efficiency directly influences the diversity of recoverable antibody-producing clones.

Fusion Antibodies employs:

• High-quality non-secreting HGPRT-deficient myeloma cell lines
• Fresh, highly viable splenocytes
• Optimised fusion conditions
• Feeder cell support for hybridoma recovery
• Stable clone establishment and expansion

These processes help maximise recovery of antigen-specific hybridoma clones suitable for downstream characterisation.

Screening and Clone Selection

Identifying functional lead antibodies requires more than simple antigen binding.

Our screening strategy is designed around the intended application and may include:

• ELISA
• Flow cytometry
• Bio-layer interferometry (BLI)
• Binding specificity analysis
• Affinity assessment
• Isotype determination
• Cross-reactivity screening

Where required, screening assays can be customised to identify antibodies with functional activity, receptor blocking or other application-specific characteristics.

Antibody Sequencing and Recombinant Expression

Once lead hybridoma clones have been identified, we recover complete variable domain sequences (VH and VL) to enable recombinant antibody production and future engineering.

Sequence recovery supports:

• Recombinant antibody generation
• Antibody reformatting
• Intellectual property protection
• Long-term reagent security
• Further optimisation and engineering

Humanisation and Lead Optimisation

For therapeutic antibody discovery programmes, mouse-derived antibodies typically require humanisation before clinical development.

Fusion Antibodies provides a seamless transition from hybridoma discovery into downstream engineering, including:

• CDR humanisation
• Affinity maturation
• Developability assessment
• Sequence optimisation
• Recombinant expression
• Cell line development

Our integrated workflow reduces project handovers while supporting efficient progression from antibody discovery towards preclinical development.

Why Fusion Antibodies?

Fusion Antibodies combines established hybridoma expertise with modern antibody engineering capabilities, providing a flexible CRO partnership for biotechnology and pharmaceutical organisations.

Our integrated capabilities include:

• Mouse Hybridoma
• Rabbit monoclonal antibody discovery
• Phage display antibody discovery
• Mammalian display technologies
• Antibody library generation and screening
• Recombinant antibody engineering
• Humanisation
• Affinity maturation
• Developability assessment
• Stable cell line development

With multiple antibody discovery platforms, we help clients select the most appropriate technology to every target.

Supporting Your End-to-End Antibody Development Programme

Mouse hybridoma is one component of Fusion Antibodies' integrated antibody discovery platform. Depending on your project requirements, hybridoma-derived antibodies can progress seamlessly into recombinant expression, humanisation, affinity maturation, developability assessment and stable cell line development.

Whether you are initiating an early-stage discovery programme or advancing therapeutic candidates towards preclinical development, our scientific teams work collaboratively to design antibody discovery strategies aligned with your technical and commercial objectives.

Ready to discuss your project?

Speak with our scientists to explore how our Mouse Hybridoma services can support your next antibody discovery programme.